TAO Synergies (TAOX) Total Non-Current Liabilities (2021 - 2026)
TAO Synergies' (TAOX) quarterly Total Non-Current Liabilities came in at $1.0 million in Q2 2026, down 3.22% on a YoY basis from $1.1 million in Q2 2025, and down 6.98% quarter-over-quarter from $1.1 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Total Non-Current Liabilities for 6 consecutive years, with $1.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Non-Current Liabilities fell 3.22% year-over-year to $1.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.0 million (down 3.22% YoY), and the FY2025 full-year result was $1.8 million, down 61.87% from the prior year.
- Total Non-Current Liabilities fell to $1.0 million in Q2 2026 per TAOX's latest filing, from $1.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $9.4 million in Q2 2024 and bottomed at $1.0 million in Q2 2026.
- Historically, Total Non-Current Liabilities has averaged $3.1 million across 5 years, with a median of $2.3 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities jumped 349.0% in 2024, then plunged 88.5% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $1.7 million in 2022, then jumped by 162.4% to $4.4 million in 2023, then grew by 8.24% to $4.8 million in 2024, then slumped by 61.87% to $1.8 million in 2025, then slumped by 42.91% to $1.0 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.0 million, $1.1 million, and $1.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | 378.37 Mn |
| 10 | TAO Synergies | 30.90 Mn | 30.90 Mn | - | 1.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.04 Mn |
| Mar 31, 2026 | 1.12 Mn |
| Dec 31, 2025 | 1.82 Mn |
| Sep 30, 2025 | 1.04 Mn |
| Jun 30, 2025 | 1.08 Mn |
| Mar 31, 2025 | 2.63 Mn |
| Dec 31, 2024 | 4.78 Mn |
| Sep 30, 2024 | 3.59 Mn |
| Jun 30, 2024 | 9.35 Mn |
| Mar 31, 2024 | 6.38 Mn |
| Dec 31, 2023 | 4.42 Mn |
| Sep 30, 2023 | 2.27 Mn |
| Jun 30, 2023 | 3.90 Mn |
| Mar 31, 2023 | 1.42 Mn |
| Dec 31, 2022 | 1.68 Mn |
| Dec 31, 2021 | -7.91 Mn |